Isoniazid/Pyrazinamide/Rifampicin

异烟肼/吡嗪酰胺/利福平

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIsoniazid/Pyrazinamide/Rifampicin
Drug Alias NameRifampicin/Isoniazid/Pyrazinamide异福酰胺片rifampicin, isoniazid and pyrazinamideRifampin - isoniazid - pyrazinamideRifater
ClassificationSmall molecules
Mechanisms of ActionFatty acid synthase inhibitorsBacterial DNA-directed RNA polymerase inhibitors
TargetsFatty acid synthaseBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsTuberculosis
Global Approved IndicationsTuberculosis
Approved Indications in ChinaTuberculosis
Original Approved Country/TerritoryUnited States
Original Approved Date1994/05/31
Country/TerritoryUnited StatesMainland China
CombinationsYes RifampicinIsoniazidPyrazinamide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesNorth China Pharmaceutical Hebei Huanuo Co Ltd
Inactive CompaniesSanofi-Aventis U.S. Llc
Active IndicationsTuberculosis
Inactive IndicationsN/A

Other Information

ATC CodeJ04AM05
Related LinksKEGG